About the Company
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA (Denosumab) for treatment of osteoporosis and bone diseases ($6.7 billion in total 2024 revenues), Enbrel (Etanercept) for treatment of autoimmune diseases ($3.3 billion in 2024 revenues), Repatha (evolocumab) for treatment of hyperlipidemia ($2.3 billion in 2024 revenues), Otezla (apremilast) for treatment of psoriasis and psoriatic arthritis ($2.1 billion in 2024 revenues), Tepezza (teprotumumab) to treat Graves' ophthalmopathy ($1.8 billion in 2024 revenues), Evenity (romosozumab) to treat osteoporosis ($1.5 billion in 2024 revenues), Kyprolis (carfilzomib) to treat cancer ($1.5 billion in 2024 revenues), Nplate (romiplostim) to regulate platelet production ($1.4 billion in 2024 revenues), and Aranesp (darbepoetin alfa) to stimulate erythropoiesis ($1.3 billion in 2024 revenues). Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on AMGEN INC
Amgen’s New Clinical Study: A Potential Game Changer in Lung Cancer Treatment
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc., in collaboration with Asher ...
Amgen’s Avacopan Study: A Potential Game Changer for Autoimmune Treatments
Amgen Inc (($AMGN)) announced an update on their ongoing clinical study. Amgen Inc. is conducting a Phase 4 clinical trial ...
Investing in Amgen (NASDAQ:AMGN) three years ago would have delivered you a 35% gain
Investors can buy low cost index fund if they want to receive the average market return. But across the board there ...
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug ...
Amgen (NASDAQ:AMGN) Has A Pretty Healthy Balance Sheet
We can see that Amgen Inc. (NASDAQ:AMGN) does use debt in its business. But the more important question is: how much risk is ...
Amgen Inc. stock outperforms competitors on strong trading day
Amgen Inc. closed 12.86% below its 52-week high of $339.17, which the company achieved on September 23rd.
Amgen Inc. stock underperforms Monday when compared to competitors
The stock's fall snapped a three-day winning streak.
Amgen to Buy ChemoCentryx for $3.7 Billion - WSJ
Amgen Inc. agreed to pay $3.7 billion in cash to acquire ChemoCentryx Inc., a biotech company with a recently approved drug to treat a rare immune-system disease.
Amgen says IRS seeks billions in back taxes, shares fall 6%
Amgen Inc on Wednesday said the U.S. Internal Revenue Service (IRS) is seeking additional back taxes of $5.1 billion, plus interest and penalties, related to the drugmaker's 2013 to 2015 ...
Amgen Agrees to Acquire Horizon Therapeutics for $27.8 Billion
Amgen Inc. AMGN -1.11% agreed to acquire Horizon Therapeutics PLC for $27.8 billion, marking the largest healthcare merger of the year. Under the terms of the deal, which was first reported by The ...
Similar Companies
Loading the latest forecasts...